Proteomics International Laboratories’ 66 per cent-owned subsidiary OxiDx has been awarded a European patent for its finger-prick technology used in monitoring and measuring levels of oxidative stress.
The company’s latest announcement triggered a flurry of interest from investors, with its shares jumping more than 10 per cent to touch $1.04 from a previous close of 96c. Management says the patent, which will remain valid until 2039, has been granted in 19 European countries and greatly expands the intellectual property protection coverage of the diagnostic test.